SYM BREAKING NEWS: A Class Action Lawsuit has been filed against Symbotic Inc. for Securities Fraud – Investors with Losses are Urged to Contact BFA Law (NASDAQ:SYM)
December 04, 2024 07:46 ET
|
Bleichmar Fonti & Auld
Symbotic Inc. investors that lost money on their investment are encouraged to contact BFA Law before February 3, 2025 legal deadline.
60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results
November 14, 2024 14:31 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma (SXTP) reported 164% revenue growth and clinical progress on ARAKODA® for infectious diseases and babesiosis in its 3Q24 earnings report.
Tecnoglass Reports Record Third Quarter 2024 Results
November 07, 2024 07:00 ET
|
Tecnoglass Inc.
- Record Revenue of $238.3 Million, Up 13.1% Year-Over-Year Driven Entirely by Organic Growth - - Single-Family Residential Revenue increased to a Record $109.7 Million, Up 25.0%...
Exosens : Poursuite de la forte dynamique de croissance et amélioration significative de la marge brute ajustée sur les 9M 2024
October 28, 2024 02:30 ET
|
Exosens
COMMUNIQUÉ DE PRESSEMÉRIGNAC, FRANCE – 28 OCTOBRE 2024 NEUF PREMIERS MOIS DE L’ANNÉE 2024 POURSUITE DE LA FORTE DYNAMIQUE DE CROISSANCE ETAMÉLIORATION SIGNIFICATIVE DE LA MARGE BRUTE...
Exosens: Continued strong growth momentum and significantly improved adjusted gross margin in 9M 2024
October 28, 2024 02:30 ET
|
Exosens
PRESS RELEASEMÉRIGNAC, FRANCE – 28 OCTOBER 2024 9M 2024 CONTINUED STRONG GROWTH MOMENTUMAND SIGNIFICANTLY IMPROVED ADJUSTED GROSS MARGIN 2024 GUIDANCE FULLY ON TRACK ...
Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow
October 17, 2024 09:32 ET
|
Tevogen Bio Inc
Total eligible patients in the US exceed 2 million.Treatment of SARS-CoV-2 infection in solid and hematologic cancer patients under active treatment.Reflects business philosophy of commercial success...
Sidetrade: 33% Increase in Revenue for Q3 2024
October 15, 2024 11:43 ET
|
Sidetrade
Q3 bookings at €1.52 million, in line for 2024 Strong revenue growth, up 33%, with SaaS subscriptions up 31% Registration completed in France’s public invoicing portal Sidetrade rises to the Top...
Sidetrade : Forte progression de 33% du chiffre d’affaires au T3 2024
October 15, 2024 11:43 ET
|
Sidetrade
Prises de commandes à 1,52 M€ sur T3, en ligne pour 2024 Forte croissance du CA à +33% dont +31% pour les abonnements SaaS Obtention de l’immatriculation au Portail Public de Facturation (PPF)...
Tevogen CEO Reaffirms the Company’s Commitment to Closing the Information Gap on Its Multi-Billion-Dollar Assets, Following the Release of Revenue Projections
October 14, 2024 18:43 ET
|
Tevogen Bio Inc
WARREN, N.J., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf,...
Tevogen Bio Plans to Share $1B+ Revenue Potential of its Pipeline Portfolio Beginning Week of October 14, 2024
October 11, 2024 15:59 ET
|
Tevogen Bio Inc
Tevogen Bio Plans to Share $1B+ Revenue Potential of its Pipeline Portfolio Beginning Week of October 14, 2024